NO851084L - Fremgangsmaate til fremstilling av somatostatinforbindeler - Google Patents

Fremgangsmaate til fremstilling av somatostatinforbindeler

Info

Publication number: NO851084L
Authority: NO; Norway
Prior art keywords: somatostatin; stated; proform; compound; natural
Prior art date: 1984-03-26

Application number

NO851084A

Other languages

English (en)

Norwegian (no)

Inventor

Georges Paul Guillaume Hennen

Jean Lambert Rene Closset

Mihn Dit Sato Tran Quang

Original Assignee

Techland Parc Ind De Rech Du S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-03-26

Filing date

1985-03-19

Publication date

1985-09-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19730232&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO851084(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1985-03-19 Application filed by Techland Parc Ind De Rech Du S filed Critical Techland Parc Ind De Rech Du S

1985-09-27 Publication of NO851084L publication Critical patent/NO851084L/no

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 23
238000004519 manufacturing process Methods 0.000 title claims abstract description 16
238000000034 method Methods 0.000 title claims description 34
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims abstract description 58
229960000553 somatostatin Drugs 0.000 claims abstract description 48
102000005157 Somatostatin Human genes 0.000 claims abstract description 47
108010056088 Somatostatin Proteins 0.000 claims abstract description 47
235000013336 milk Nutrition 0.000 claims abstract description 7
239000008267 milk Substances 0.000 claims abstract description 7
210000004080 milk Anatomy 0.000 claims abstract description 7
-1 phenyl- Chemical group 0.000 claims description 27
108090000765 processed proteins & peptides Proteins 0.000 claims description 27
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 26
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 26
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 24
GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 claims description 21
150000001413 amino acids Chemical class 0.000 claims description 19
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
235000001014 amino acid Nutrition 0.000 claims description 18
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 claims description 16
238000006467 substitution reaction Methods 0.000 claims description 14
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 12
102000018997 Growth Hormone Human genes 0.000 claims description 11
108010051696 Growth Hormone Proteins 0.000 claims description 11
239000002253 acid Chemical group 0.000 claims description 11
150000002148 esters Chemical class 0.000 claims description 10
239000000122 growth hormone Substances 0.000 claims description 10
238000002347 injection Methods 0.000 claims description 10
239000007924 injection Substances 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 10
230000002163 immunogen Effects 0.000 claims description 9
101000633010 Rattus norvegicus Somatostatin Proteins 0.000 claims description 8
239000000546 pharmaceutical excipient Substances 0.000 claims description 8
NHXLMOGPVYXJNR-UHFFFAOYSA-N srif Chemical compound N1C(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(CC=2C3=CC=CC=C3NC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)CNC(=O)C(C)N)CSSCC(C(O)=O)NC(=O)C(CO)NC(=O)C(C(O)C)NC(=O)C1CC1=CC=CC=C1 NHXLMOGPVYXJNR-UHFFFAOYSA-N 0.000 claims description 8
125000003277 amino group Chemical group 0.000 claims description 7
244000144972 livestock Species 0.000 claims description 6
239000003153 chemical reaction reagent Substances 0.000 claims description 5
230000028327 secretion Effects 0.000 claims description 5
125000000217 alkyl group Chemical group 0.000 claims description 4
125000003118 aryl group Chemical group 0.000 claims description 4
150000003857 carboxamides Chemical group 0.000 claims description 4
125000004122 cyclic group Chemical group 0.000 claims description 4
125000000524 functional group Chemical group 0.000 claims description 4
229910052739 hydrogen Inorganic materials 0.000 claims description 4
239000001257 hydrogen Substances 0.000 claims description 4
238000010255 intramuscular injection Methods 0.000 claims description 4
239000007927 intramuscular injection Substances 0.000 claims description 4
229940124530 sulfonamide Drugs 0.000 claims description 4
150000003456 sulfonamides Chemical group 0.000 claims description 4
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
150000003568 thioethers Chemical group 0.000 claims description 4
150000001412 amines Chemical group 0.000 claims description 3
229920000642 polymer Polymers 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
238000010254 subcutaneous injection Methods 0.000 claims description 3
239000007929 subcutaneous injection Substances 0.000 claims description 3
NMAKGCMEDYICRN-UHFFFAOYSA-N 2-[[4-[2-[2-(2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl)oxypropanoylamino]propanoylamino]-5-amino-5-oxopentanoyl]amino]-6-aminoheptanedioic acid Chemical compound OCC(O)C(O)C(C(NC(C)=O)C=O)OC(C)C(=O)NC(C)C(=O)NC(C(N)=O)CCC(=O)NC(CCCC(N)C(O)=O)C(O)=O NMAKGCMEDYICRN-UHFFFAOYSA-N 0.000 claims description 2
150000008574 D-amino acids Chemical class 0.000 claims description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 2
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical group ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
239000004473 Threonine Substances 0.000 claims description 2
125000002877 alkyl aryl group Chemical group 0.000 claims description 2
229940124277 aminobutyric acid Drugs 0.000 claims description 2
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 2
125000003710 aryl alkyl group Chemical group 0.000 claims description 2
235000003704 aspartic acid Nutrition 0.000 claims description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
238000009833 condensation Methods 0.000 claims description 2
230000005494 condensation Effects 0.000 claims description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
238000001212 derivatisation Methods 0.000 claims description 2
229940059082 douche Drugs 0.000 claims description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 2
239000004220 glutamic acid Substances 0.000 claims description 2
235000013922 glutamic acid Nutrition 0.000 claims description 2
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 2
230000013595 glycosylation Effects 0.000 claims description 2
238000006206 glycosylation reaction Methods 0.000 claims description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
125000000623 heterocyclic group Chemical group 0.000 claims description 2
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 2
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims description 2
229950003188 isovaleryl diethylamide Drugs 0.000 claims description 2
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 2
108700030295 muramylNAc-Ala-isoGln-Lys-tripeptide Proteins 0.000 claims description 2
229960003104 ornithine Drugs 0.000 claims description 2
238000010647 peptide synthesis reaction Methods 0.000 claims description 2
125000000405 phenylalanyl group Chemical group 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
229910052711 selenium Inorganic materials 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
229960003080 taurine Drugs 0.000 claims description 2
150000007970 thio esters Chemical class 0.000 claims description 2
125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
125000005454 tryptophanyl group Chemical group 0.000 claims description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
125000000837 carbohydrate group Chemical group 0.000 claims 2
230000001747 exhibiting effect Effects 0.000 claims 2
125000001288 lysyl group Chemical group 0.000 claims 2
125000001980 alanyl group Chemical group 0.000 claims 1
239000012876 carrier material Substances 0.000 claims 1
230000003053 immunization Effects 0.000 claims 1
238000002649 immunization Methods 0.000 claims 1
238000010188 recombinant method Methods 0.000 claims 1
239000011669 selenium Substances 0.000 claims 1
125000002072 seryl group Chemical group 0.000 claims 1
125000002114 valyl group Chemical group 0.000 claims 1
241001465754 Metazoa Species 0.000 abstract description 50
238000010168 coupling process Methods 0.000 abstract description 15
238000005859 coupling reaction Methods 0.000 abstract description 15
230000008878 coupling Effects 0.000 abstract description 13
239000000203 mixture Substances 0.000 description 37
238000006243 chemical reaction Methods 0.000 description 21
239000000243 solution Substances 0.000 description 14
229960005486 vaccine Drugs 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
238000011282 treatment Methods 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
239000002904 solvent Substances 0.000 description 9
235000019786 weight gain Nutrition 0.000 description 9
230000004584 weight gain Effects 0.000 description 9
239000000047 product Substances 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
239000012153 distilled water Substances 0.000 description 7
238000000921 elemental analysis Methods 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000011161 development Methods 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
239000007787 solid Substances 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
238000002255 vaccination Methods 0.000 description 6
150000001720 carbohydrates Chemical group 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
239000005556 hormone Substances 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
238000000746 purification Methods 0.000 description 5
239000000725 suspension Substances 0.000 description 5
241000283690 Bos taurus Species 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
229960000583 acetic acid Drugs 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
239000012156 elution solvent Substances 0.000 description 4
125000004435 hydrogen atom Chemical class [H]* 0.000 description 4
239000002609 medium Substances 0.000 description 4
210000004400 mucous membrane Anatomy 0.000 description 4
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
102000011022 Chorionic Gonadotropin Human genes 0.000 description 3
108010062540 Chorionic Gonadotropin Proteins 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
230000027455 binding Effects 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
229940084986 human chorionic gonadotropin Drugs 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
239000002502 liposome Substances 0.000 description 3
235000013372 meat Nutrition 0.000 description 3
230000008018 melting Effects 0.000 description 3
238000002844 melting Methods 0.000 description 3
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
229940126577 synthetic vaccine Drugs 0.000 description 3
238000004809 thin layer chromatography Methods 0.000 description 3
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
229920002873 Polyethylenimine Polymers 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
230000001195 anabolic effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
244000309464 bull Species 0.000 description 2
SAKUKAQFBMDKGX-UHFFFAOYSA-N butan-1-ol;2-pyridin-2-ylacetic acid;hydrate Chemical compound O.CCCCO.OC(=O)CC1=CC=CC=N1 SAKUKAQFBMDKGX-UHFFFAOYSA-N 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
HYGYSIDIKIGPJA-UHFFFAOYSA-N chloroform;ethyl acetate;methanol Chemical compound OC.ClC(Cl)Cl.CCOC(C)=O HYGYSIDIKIGPJA-UHFFFAOYSA-N 0.000 description 2
239000013078 crystal Substances 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
235000018823 dietary intake Nutrition 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000001508 eye Anatomy 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000012467 final product Substances 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
230000003308 immunostimulating effect Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
210000001331 nose Anatomy 0.000 description 2
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
239000003208 petroleum Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
241000894007 species Species 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000001308 synthesis method Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 2
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
WKFYEWXSRFQOKX-UHFFFAOYSA-N 1,4-dioxane;toluene Chemical compound C1COCCO1.CC1=CC=CC=C1 WKFYEWXSRFQOKX-UHFFFAOYSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
GAWAYYRQGQZKCR-UHFFFAOYSA-N 2-chloropropionic acid Chemical compound CC(Cl)C(O)=O GAWAYYRQGQZKCR-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
101800000736 Growth hormone-releasing factor Proteins 0.000 description 1
102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testosterone Natural products O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
MTEUMURLJRZUKD-UHFFFAOYSA-N acetic acid;butan-1-ol;pyridine;hydrate Chemical compound O.CC(O)=O.CCCCO.C1=CC=NC=C1 MTEUMURLJRZUKD-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
OJYGBLRPYBAHRT-UHFFFAOYSA-N alphachloralose Chemical compound O1C(C(Cl)(Cl)Cl)OC2C(O)C(C(O)CO)OC21 OJYGBLRPYBAHRT-UHFFFAOYSA-N 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
IPDQVJYWUCDNBB-UHFFFAOYSA-N chloroform;2,2,2-trifluoroacetic acid Chemical compound ClC(Cl)Cl.OC(=O)C(F)(F)F IPDQVJYWUCDNBB-UHFFFAOYSA-N 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
230000007423 decrease Effects 0.000 description 1
239000012954 diazonium Chemical group 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical group [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
125000006286 dichlorobenzyl group Chemical group 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
239000007952 growth promoter Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical group [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
229960002700 octreotide Drugs 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
125000005254 oxyacyl group Chemical group 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical group O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical group OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
239000012264 purified product Substances 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000000384 rearing effect Effects 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000032365 regulation of testosterone secretion Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000012265 solid product Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000009466 transformation Effects 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000011592 zinc chloride Substances 0.000 description 1
235000005074 zinc chloride Nutrition 0.000 description 1
JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/5555—Muramyl dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6062—Muramyl peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Toxicology (AREA)
Biotechnology (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Crystallography & Structural Chemistry (AREA)
Obesity (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Fodder In General (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Feed For Specific Animals (AREA)

NO851084A 1984-03-26 1985-03-19 Fremgangsmaate til fremstilling av somatostatinforbindeler NO851084L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
LU85269A LU85269A1 (fr)	1984-03-26	1984-03-26	Composes nouveaux de somatostatine,procede pour leur synthese,preparation a usage veterinaire contenant lesdits composes et procede pour le traitement d'animaux

Publications (1)

Publication Number	Publication Date
NO851084L true NO851084L (no)	1985-09-27

Family

ID=19730232

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO851084A NO851084L (no)	1984-03-26	1985-03-19	Fremgangsmaate til fremstilling av somatostatinforbindeler

Country Status (14)

Country	Link
EP (1)	EP0157753B1 (da)
JP (1)	JPS60222499A (da)
KR (1)	KR850006942A (da)
AT (1)	ATE30729T1 (da)
AU (1)	AU4037485A (da)
DE (1)	DE3560949D1 (da)
DK (1)	DK133085A (da)
ES (1)	ES8605147A1 (da)
GR (1)	GR850746B (da)
IL (1)	IL74701A0 (da)
LU (1)	LU85269A1 (da)
NO (1)	NO851084L (da)
PT (1)	PT80159B (da)
ZA (1)	ZA852224B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4599229A (en) *	1985-09-09	1986-07-08	International Minerals & Chemical Corp.	Method of promoting animal growth using antibodies against somatostatin
HU206890B (en) *	1986-10-13	1993-01-28	Sandoz Ag	Process for producing sugar-modified somatostatin peptide derivatives and pharmaceutical compositions containing them as active components
CH679045A5 (da) *	1987-06-29	1991-12-13	Sandoz Ag
FR2622455B1 (fr) *	1987-11-04	1991-07-12	Agronomique Inst Nat Rech	Application du facteur de stimulation de la secretion de l'hormone de croissance humaine, de ses fragments actifs et des analogues correspondants, pour augmenter la production laitiere et le poids des nouveau-nes chez les mammiferes
US5552534A (en) *	1991-08-22	1996-09-03	The Trustees Of The University Of Pennsylvania	Non-Peptide peptidomimetics
WO1993013791A1 (en) *	1992-01-20	1993-07-22	Peptech (Uk) Limited	Use of muramyl peptides for enhancing animal production
IT1283134B1 (it) *	1996-07-08	1998-04-07	Dox Al Italia Spa	Derivati sintetici e semisintetici di somatostatine utili nella stimolazione della crescita corporea, in particolare in
HK1048828A1 (zh)	1999-11-19	2003-04-17	Transkaryotic Therapies, Inc.	可令生产优化的核酸构造
FR2852247A1 (fr) *	2003-03-11	2004-09-17	Centre Nat Rech Scient	Utilisation de ligands peptidiques de recepteurs de la membrane plasmique et de leurs analogues pour moduler l'activite des mitochondries
BR112014004784A2 (pt) *	2011-09-04	2017-03-21	Glytech Inc	polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo
WO2013032012A1 (ja)	2011-09-04	2013-03-07	株式会社糖鎖工学研究所	糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2522967B1 (fr) *	1982-03-15	1986-03-07	Anvar	Conjugues d'haptenes et de muramyl-peptides, doues d'activite immunogene et compositions les contenant

1984
- 1984-03-26 LU LU85269A patent/LU85269A1/fr unknown
1985
- 1985-03-19 NO NO851084A patent/NO851084L/no unknown
- 1985-03-20 DE DE8585870041T patent/DE3560949D1/de not_active Expired
- 1985-03-20 AT AT85870041T patent/ATE30729T1/de not_active IP Right Cessation
- 1985-03-20 EP EP85870041A patent/EP0157753B1/en not_active Expired
- 1985-03-25 DK DK133085A patent/DK133085A/da not_active Application Discontinuation
- 1985-03-25 IL IL74701A patent/IL74701A0/xx unknown
- 1985-03-25 PT PT80159A patent/PT80159B/pt unknown
- 1985-03-25 ZA ZA852224A patent/ZA852224B/xx unknown
- 1985-03-25 ES ES541532A patent/ES8605147A1/es not_active Expired
- 1985-03-25 JP JP60060517A patent/JPS60222499A/ja active Pending
- 1985-03-26 GR GR850746A patent/GR850746B/el unknown
- 1985-03-26 KR KR1019850001984A patent/KR850006942A/ko not_active Withdrawn
- 1985-03-26 AU AU40374/85A patent/AU4037485A/en not_active Abandoned

Also Published As

Publication number	Publication date
ES8605147A1 (es)	1986-04-01
LU85269A1 (fr)	1985-10-14
IL74701A0 (en)	1985-06-30
PT80159A (en)	1985-04-01
DE3560949D1 (en)	1987-12-17
JPS60222499A (ja)	1985-11-07
EP0157753B1 (en)	1987-11-11
PT80159B (en)	1986-11-10
DK133085D0 (da)	1985-03-25
KR850006942A (ko)	1985-10-25
ATE30729T1 (de)	1987-11-15
DK133085A (da)	1985-09-27
EP0157753A1 (en)	1985-10-09
GR850746B (da)	1986-05-13
ES541532A0 (es)	1986-04-01
ZA852224B (en)	1985-11-27
AU4037485A (en)	1985-10-03

Publication	Publication Date	Title
JP2744910B2 (ja)	1998-04-28	ペプチド誘導体類
Metzger et al.	1991	Synthesis of novel immunologically active tripalmitoyl‐S‐glycerylcysteinyl lipopeptides as useful intermediates for immunogen preparations
DK172399B1 (da)	1998-05-18	Konjugat af aktivt stof og membranankerforbindelse, dets fremstilling samt anvendelse
US5847066A (en)	1998-12-08	Analogs of growth hormone-releasing factor
JP3915125B2 (ja)	2007-05-16	ニトロシル化神経ペプチド、その類似体、断片または誘導体より成る化合物とその使用法
NO179164B (no)	1996-05-13	Fremgangsmåte for fremstilling av et immunogenkonjugat
NO151201B (no)	1984-11-19	Fremgangsmaate for fremstilling av terapeutisk virksomme antigenderivater.
US6074650A (en)	2000-06-13	Membrane anchor/active compound conjugate, its preparation and its uses
US6024964A (en)	2000-02-15	Membrane anchor/active compound conjugate, its preparation and its uses
US20070134259A1 (en)	2007-06-14	Methods and compositions for pharmacologially controlled targeted immunotherapy
JPH0720882B2 (ja)	1995-03-08	免疫原活性を付与されたハプテンとムラムル―ペプチドとの組成物
WO1991008220A1 (en)	1991-06-13	A method for the stepwise, controlled synthesis of chemical species, particularly peptides, coupled products obtained by the method and the use of these coupled products, e.g. as vaccines
CN104936613B (zh)	2018-05-22	糖链加成连接子、含有糖链加成连接子与生理活性物质的化合物或其盐、以及其制造方法
EP0157753B1 (en)	1987-11-11	New somatostatin compounds, process for their synthesis, preparation for veterinary use containing said compound and process for the treatment of animals
JP2006514981A (ja)	2006-05-18	Ｇｐ１２０特異抗原、その結合体；その調製と使用のための方法
Zeng et al.	1996	Synthesis of a new template with a built‐in adjuvant and its use in constructing peptide vaccine candidates through polyoxime chemistry
US4693998A (en)	1987-09-15	Novel compounds of the muramyl peptide
US20240148863A1 (en)	2024-05-09	Carrier protein for peptide antigen
AU619826B2 (en)	1992-02-06	A synthetic vaccine against foot and mouth disease and a process for the preparation thereof
GB2282813A (en)	1995-04-19	Annular antigen scaffolds comprising thioether linkages
CA2233882A1 (en)	1997-05-01	Pseudomonas exotoxin as immunogenic carrier in synthetic conjugate vaccines
IE920055A1 (en)	1992-07-15	Improvements in and relating to hormones
US6335320B1 (en)	2002-01-01	Method of treating fibrotic conditions
JPH0137400B2 (da)	1989-08-07
WO2011109106A2 (en)	2011-09-09	Immunogenic compositions against human progastrin peptides